Skip to main content
OpenTrials

Clinical trial condition

Adenocarcinoma, Papillary

Explore clinical trials studying Adenocarcinoma, Papillary. Study availability and eligibility vary by location and protocol.

137 public trials 26 recruiting studies
Refine in advanced search Browse all conditions

Adenocarcinoma, Papillary trial results

Active, Not Recruiting

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

NCT03899792

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Breast Diseases, +52 more
Locations
  • Childrens Hospital of Los Angeles Los Angeles, California, United States
  • The Children's Hospital for Cancer and Blood Disorders Aurora, Colorado, United States
  • Nemours Children's Health Orlando, Florida, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 26 locations
View Trial Details
Active, Not Recruiting

Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer

NCT04624477

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Carcinoma, +14 more
Locations
  • University of Calgary, Cumming School of Medicine Calgary, Alberta, Canada
  • University of British Columbia Vancouver, British Columbia, Canada
  • Nova Scotia Health Halifax, Nova Scotia, Canada
  • St. Joseph's Healthcare Hamilton, Ontario, Canada
View Trial Details
Active, Not Recruiting

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

NCT04544111

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +22 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities) Commack, New York, United States
View Trial Details
Active, Not Recruiting

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

NCT03690388

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +13 more
Locations
  • Exelixis Clinical Site #2 Newport Beach, California, United States
  • Exelixis Clinical Site #98 Sacramento, California, United States
  • Exelixis Clinical Site #69 San Francisco, California, United States
  • Exelixis Clinical Site #10 Stanford, California, United States
View all 164 locations
View Trial Details

Related conditions